# MeiraGTx Reports First Quarter 2026 Financial and Operational Results
Canonical URL: https://biopharmsignal.com/news/MGTX/meiragtx-reports-first-quarter-2026-financial-and-operational-results
Ticker: MGTX
Company: MeiraGTx
Source: MeiraGTx
Published: 2026-05-14 12:00 EST
Original Source URL: https://investors.meiragtx.com
## Summary

Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 Reported positive three-year data from the Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomia Entered into an asset purchase agreement with Johnson & Johnson* (J&J) to acquire all interests

## Article Body
Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 Reported positive three-year data from the Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomia Entered into an asset purchase agreement with Johnson & Johnson* (J&J) to acquire all interests
## Recent Company News
- 2026-05-14 20:30 EST — [MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/MGTX/meiragtx-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4) — Source: MeiraGTx
- 2026-05-14 12:00 EST — [MeiraGTx Reports First Quarter 2026 Financial and Operational Results](https://biopharmsignal.com/news/MGTX/meiragtx-reports-first-quarter-2026-financial-and-operational-results) — Source: MeiraGTx
- 2026-04-16 11:48 EST — [MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares](https://biopharmsignal.com/news/MGTX/meiragtx-announces-pricing-of-100-million-offering-of-ordinary-shares) — Source: MeiraGTx
- 2026-04-16 11:10 EST — [MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)](https://biopharmsignal.com/news/MGTX/meiragtx-announces-the-acquisition-of-botaretigene-sparoparvovec-bota-vec-for-the-treatment-of-x-linked-retinitis-pigmentosa-xlrp) — Source: MeiraGTx
- 2026-04-16 11:00 EST — [MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia](https://biopharmsignal.com/news/MGTX/meiragtx-announces-positive-three-year-data-from-the-phase-1-aquax-clinical-study-of-aav-haqp1-for-the-treatment-of-grade-2-3-late-radiation-induced-xerostomia) — Source: MeiraGTx
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)